Log In
Print
BCIQ
Print
Print this Print this
 

Catioprost (Nova21027)

  Manage Alerts
Collapse Summary General Information
Company Santen Pharmaceutical Co. Ltd.
DescriptionOcular formulation of latanoprost using Novasorb cationic emulsion technology
Molecular Target Prostaglandin F (FP) receptor (PTGFR)
Mechanism of ActionProstaglandin F (FP) receptor agonist
Latest Stage of DevelopmentPhase II
IndicationGlaucoma
Partner

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today